Detalles de la búsqueda
1.
A Randomized Phase 3 Study Comparing P2B001 to its Components (Low-Dose Extended-Release Rasagiline and Pramipexole) and to Optimized Doses of Marketed Extended-Release Pramipexole in Early Parkinson's Disease.
Mov Disord
; 39(2): 350-359, 2024 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-37886872
2.
A randomized trial of a low-dose Rasagiline and Pramipexole combination (P2B001) in early Parkinson's disease.
Mov Disord
; 32(5): 783-789, 2017 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-28370340
3.
Pyridostigmine in the treatment of postural orthostatic tachycardia: a single-center experience.
Pacing Clin Electrophysiol
; 34(6): 750-5, 2011 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-21410722
4.
Video Representation of Dopamine-Responsive Multiple System Atrophy Cerebellar Type.
Am J Case Rep
; 22: e933995, 2021 Nov 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-34776506
5.
Treatment of early Parkinson's disease. Part 1.
Eur Neurol
; 61(4): 193-205, 2009.
Artículo
en Inglés
| MEDLINE | ID: mdl-19176960
6.
Treatment of early Parkinson's disease. Part 2.
Eur Neurol
; 61(4): 206-15, 2009.
Artículo
en Inglés
| MEDLINE | ID: mdl-19176961
7.
Prevalence of Dyskinesia and OFF by 30-Minute Intervals Through the Day and Assessment of Daily Episodes of Dyskinesia and OFF: Novel Analyses of Diary Data from Gocovri Pivotal Trials.
J Parkinsons Dis
; 9(3): 591-600, 2019.
Artículo
en Inglés
| MEDLINE | ID: mdl-31081793
8.
Pooled Analyses of Phase III Studies of ADS-5102 (Amantadine) Extended-Release Capsules for Dyskinesia in Parkinson's Disease.
CNS Drugs
; 32(4): 387-398, 2018 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-29532440
9.
Author Correction to: Pooled Analyses of Phase III Studies of ADS-5102 (Amantadine) Extended-Release Capsules for Dyskinesia in Parkinson's Disease.
CNS Drugs
; 32(4): 399-400, 2018 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-29637528
10.
Optimizing extended-release carbidopa/levodopa in Parkinson disease: Consensus on conversion from standard therapy.
Neurol Clin Pract
; 7(1): 86-93, 2017 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-28243505
11.
Safety of Converting From Tetrabenazine to Deutetrabenazine for the Treatment of Chorea.
JAMA Neurol
; 74(8): 977-982, 2017 08 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-28692723
12.
The Efficacy Profile of Rotigotine During the Waking Hours in Patients With Advanced Parkinson's Disease: A Post Hoc Analysis.
Clin Neuropharmacol
; 39(2): 88-93, 2016.
Artículo
en Inglés
| MEDLINE | ID: mdl-26882318
13.
Acoustic analysis of clear versus conversational speech in individuals with Parkinson disease.
J Commun Disord
; 38(3): 215-30, 2005.
Artículo
en Inglés
| MEDLINE | ID: mdl-15748725
14.
Posterior Reversible Encephalopathy Syndrome Secondary to CSF Leak and Intracranial Hypotension: A Case Report and Literature Review.
Case Rep Neurol Med
; 2015: 538523, 2015.
Artículo
en Inglés
| MEDLINE | ID: mdl-26106495
15.
Impact of 6-month earlier versus postponed initiation of rotigotine on long-term outcome: post hoc analysis of patients with early Parkinson's disease with mild symptom severity.
Expert Opin Pharmacother
; 16(10): 1423-33, 2015.
Artículo
en Inglés
| MEDLINE | ID: mdl-25997442
16.
Conversion to IPX066 from Standard Levodopa Formulations in Advanced Parkinson's Disease: Experience in Clinical Trials.
J Parkinsons Dis
; 5(4): 837-45, 2015.
Artículo
en Inglés
| MEDLINE | ID: mdl-26444090
17.
A randomized study of rotigotine dose response on 'off' time in advanced Parkinson's disease.
J Parkinsons Dis
; 4(3): 361-73, 2014.
Artículo
en Inglés
| MEDLINE | ID: mdl-24643203
18.
Rasagiline adjunct therapy in patients with Parkinson's disease: post hoc analyses of the PRESTO and LARGO trials.
Parkinsonism Relat Disord
; 19(11): 930-6, 2013 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-23849501
19.
Long-term safety and tolerability of rotigotine transdermal system in patients with early-stage idiopathic Parkinson's disease: a prospective, open-label extension study.
Parkinsonism Relat Disord
; 18(5): 488-93, 2012 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-22326237
20.
Orally disintegrating selegiline in Parkinson patients with dopamine agonist-related adverse effects.
Clin Neuropharmacol
; 33(1): 5-10, 2010.
Artículo
en Inglés
| MEDLINE | ID: mdl-19855267